Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The clinical effectiveness of opioid maintenance for heroin dependence is believed to result from a medication's ability to decrease mu-opioid receptor (muOR) availability thereby replacing agonist effects, alleviating withdrawal symptoms and attenuating heroin effects. We empirically tested this hypothesis in five heroin-dependent volunteers who were successively maintained on 32, 16, 2, and 0 mg daily buprenorphine (BUP) tablet doses. We predicted and confirmed that higher BUP doses would decrease in vivo muOR availability (measured with PET and [(11)C]carfentanil), increase plasma levels of BUP and its metabolite nor-BUP, and decrease withdrawal symptoms and hydromorphone (HYD) responses. Relative to placebo, BUP significantly decreased mean (+/-SEM) whole-brain muOR availability 41+/-8, 80+/-2, and 84+/-2% at 2, 16, and 32 mg, respectively. Regions of interest (ROIs) (prefrontal cortex, anterior cingulate, thalamus, amygdala, nucleus accumbens, caudate) showed similar dose-dependent effects. Changes in muOR availability varied across ROIs (prefrontal cortex, 47% vs amygdala, 27%) at BUP 2 mg, but were more homogeneous across ROIs at BUP 32 mg (94-98%; except thalamus, 88%). Relative to placebo (0 ng/ml), peak plasma levels of BUP and nor-BUP were comparable and dose-dependent (0.5-1, 5-6, and 13-14 ng/ml at 2, 16, and 32 mg, respectively). muOR availability decreases were negatively correlated with BUP plasma level and positively correlated with questionnaire-based opioid withdrawal symptoms and attenuation of HYD symptoms. These findings suggest that high-dose BUP maintenance produces near-maximal muOR occupation, muOR availability correlates well with plasma levels, and BUP-related opioid symptoms and antagonist blockade exhibit concentration-effect relationships.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“We derived a curve of best fit for buprenorphine from dose-occupancy data in Greenwald et al. 17 (as reported in Greenwald et al. 18 ) where occupancy was measured 4 h after 12 days of maintenance treatment with doses ranging from 1 to 32 mg (Figure 2 and Table 3).”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“This was corroborated by Greenwald et al. (117) who found that higher buprenorphine doses (up to 32 mg given as a tablet*) led to increased plasma buprenorphine levels, decreased μ-opioid receptor availability, and decreased withdrawal symptoms.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
In the citing paper
“In the same study, heroin craving was found to be significantly correlated with μ-opioid receptor availability and negatively correlated with buprenorphine plasma levels.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688 · cited 1×
“The global binding potential value was calculated using SPM99 (Friston et al, 1995) as the average value across all brain voxels.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“An experienced clinician administered a semistructured interview (SCID-IV; First et al, 1996), and opioid dependence severity was determined using the Addiction Severity Index (McLellan et al, 1985a, b).”
MethodMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Earlier human laboratory studies showed that administration of subcutaneous BUP (Jasinski et al, 1978; Mello et al, 1982) or sublingual BUP liquid (Bickel et al, 1988; Rosen et al, 1994; Walsh et al, 1995) could attenuate the reinforcing, subjective, and physiological effects of mOR agonists.”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethodAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Meyer, C. R., Boes, J. L., Kim, B., Bland, P. H., Zasadny, K. R., Kison, P. V., Koral, K., Frey, K. A., & Wahl, R. L. (1997) · Medical Image Analysis · doi:10.1016/s1361-8415(97)85010-4 · Cited by 460
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethod
Research works printed but not linked: 2
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis Disorders—Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York.
- Lewis JW, Rance MJ, Sanger DJ (1983). The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK (ed). Advances in Substance Abuse Vol. 3 JAI Press: Greenwich, 103–154.
Cited by
Items 201–300 of 348
Allen, S. M., Nichols, T. A., Fawcett, J., & Lin, S. (2022) · American Journal on Addictions · doi:10.1111/ajad.13267 · Cited by 6
Soyer, A., Leterrier, S., Breuil, L., Goislard, M., Leroy, C., Saba, W., Thibault, K., Bo, G. D., Bottlaender, M., Caillé, F., et al. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1181786 · Cited by 6
WALSH, S. L., Comer, S. D., Zdovc, J. A., Sarr, C., Björnsson, M. A., Strandgården, K., Hjelmström, P., & Tiberg, F. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01793-z · Cited by 6
Patients on Buprenorphine Formulations Undergoing Surgery
Champagne, K., Date, P., Forero, J. P., Arany, J., & Gritsenko, K. (2022) · Current Pain and Headache Reports · doi:10.1007/s11916-022-01046-6 · Cited by 6
Neurochemical Imaging of Addictive Disorders
Broft, A. I., & Martínez, D. (2012) · Neuromethods · doi:10.1007/7657_2012_48 · Cited by 6
Miles, R., Wanklyn, S., & Ross, J. R. (2021) · doi:10.1093/med/9780198821328.003.0038 · Cited by 6
Hakomäki, H., Eskola, S., Kokki, H. J., Lehtonen, M., Rasanen, J. P., Laaksonen, S., Voipio, H., Ranta, V., & Kokki, M. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106283 · Cited by 6
Santiago, D., Sanjuan, V. M., Melín, K., Duconge-Soler, J., Zhao, W., & Venkataramanan, R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121226 · Cited by 6
Joyal, K., Peckham, A. M., Wakeman, S. E., Zlotoff, D., Lewis, G. D., D’Alessandro, D., Crowley, J. C., & Waldman, G. (2021) · Transplantation · doi:10.1097/tp.0000000000003926 · Cited by 6
Τσακιρίδου, Γ., Angelerou, M.-F.-G., Efentakis, P., Margaritis, A., Papanastasiou, A.-M., & Kalantzi, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010021 · Cited by 5
Soyer, A., Leterrier, S., Goutal, S., Corvo, C., Saba, W., Caillé, F., Bo, G. D., Winkeler, A., Thibault, K., Leroy, C., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117848 · Cited by 5
Insurmountable antagonism of human mu opioid receptors by buprenorphine is due to hemi-equilibrium
Wedemeyer, M. J., Chavera, T. S., Berg, K. A., & Clarke, W. P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177192 · Cited by 5
Buprenorphine–naloxone buccal soluble film for the treatment of opioid dependence: current update
Soyka, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.953479 · Cited by 5
Garavan, H., Lingford-Hughes, A. R., Jones, T., Morris, P. G., Rothwell, J. C., & Williams, S. (2007) · Elsevier eBooks · doi:10.1016/b978-012370624-9/50012-8 · Cited by 5
Hammers, A., & Lingford-Hughes, A. R. (2007) · PET Clinics · doi:10.1016/j.cpet.2007.09.006 · Cited by 5
Youngblood, B. D., Medina, J. C., Gehlert, D. R., & Schwartz, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1170541 · Cited by 5
Opioid addiction, opioid addiction treatment, and HIV infection.
Bruce, R. D. (2018) · Europe PMC (PubMed Central) · Cited by 5
Cross-tolerance and μ agonist efficacy in pigeons treated with LAAM or buprenorphine
Galici, R., McMahon, L. R., & FRANCE, C. J. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.05.003 · Cited by 5
Treatment of Opioid Dependence
Saxon, A. J. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131.ch005 · Cited by 5
Basal cortisol level modulates stress-induced opioid-seeking behavior
Greenwald, M. K., Woodcock, E. A., Moses, T. E. H., & Lundahl, L. H. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100684 · Cited by 5
Self-citationVais, S., Starr, N. E., Castro, M., Brand, N. R., Murphy, A., Tesoriero, R., & Kryzhanovskaya, I. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001279 · Cited by 4
Stein, B. D., Sheng, F., Saloner, B. K., Gordon, A. J., & Merlin, J. S. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00547-0 · Cited by 4
Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders
Greenwald, M. K., & Steinmiller, C. L. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_3 · Cited by 4
Self-citationAgonist-antagonist combinations in opioid dependence: a translational approach.
Mannelli, P. (2010) · PubMed · Cited by 4
Alalade, E., Bilinovic, J., Walch, A. G., Burrier, C., McKee, C. T., & Tobias, J. D. (2020) · Journal of Pain Research · doi:10.2147/jpr.s222885 · Cited by 4
Alsmadi, M. M. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001172 · Cited by 4
Hochdosis-Buprenorphin im Rahmen der ambulant-palliativen Schmerztherapie
Gastmeier, K., & Freye, E. C. K. (2008) · Der Schmerz · doi:10.1007/s00482-008-0742-9 · Cited by 4
Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists
Walker, E. A., & Comer, S. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-197-0_9 · Cited by 4
Reduced need for inpatient care following introduction of long-acting injectable buprenorphine
Gauffin, E., Franca, A. M., Ferrero, E. P., Freij, Z., Pihlflyckt, I., Sandell, M., Gedeon, C., Zhang, H., Andersson, D., Tinghög, G., et al. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13607-7 · Cited by 3
Positron Emission Tomography (PET) Imaging of Opioid Receptors
van Waarde, A., Absalom, A. R., Visser, A. K. D., & Dierckx, R. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_20 · Cited by 3
Fang, X., Zhao, Y., Yao, Y., Qin, J., Lin, Y., Yang, J., & Xu, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1412099 · Cited by 3
Clearance of buprenorphine during pregnancy and neonatal outcomes
Coker, J. L., Ray-Griffith, S. L., McLeod, C., Han, X., Mancino, M. J., Kearns, G. L., & Stowe, Z. N. (2021) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01128-1 · Cited by 3
Borris, J. B., Dowd-Green, C., Bowman, L. A., Nesbit, S. A., Fingerhood, M., & Stewart, R. W. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209209 · Cited by 3
Managing Patients with Chronic Pain and Opioid Addiction
Taylor, D. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-08111-3 · Cited by 3
Buprenorphine - opioid with unique properties
Kocot-Kępska, M., Przeklasa-Muszyńska, A., & Dobrogowski, J. (2016) · Palliative Medicine in Practice · Cited by 3
State-of-The-Art Treatment of Opioid Use Disorder
Mooney, L. J., & Saxon, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00006-7 · Cited by 3
Buprenorphine management: a conundrum for the anesthesiologist and beyond - a one-act play
Thakrar, S. P., Lee, J., Martin, C. E., & Butterworth, J. F. I. (2020) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2020-101294 · Cited by 3
Mu Opioid Receptor Dynamics in Healthy Volunteers with a History of Childhood Maltreatment
Hill, K., Hsu, D. T., Taylor, S. F., Ogden, R. T., Parsey, R. V., & DeLorenzo, C. (2022) · Journal of Child & Adolescent Trauma · doi:10.1007/s40653-022-00463-4 · Cited by 3
Gu, M., Li, A., Mak, W. Y., Dong, F., Xu, N., Zhang, J., Shi, Y., Zheng, N., Tang, Z., He, Q., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1089862 · Cited by 3
Soyka, M., & Hillemacher, T. (2013) · Addiction · doi:10.1111/add.12376 · Cited by 3
Buprenorphine Prescribing and Dosing Limits: Evidence and Policy Goals
Coyle, D. T., Stewart, S. B., Bortz, C., Manalo, J., Ritvo, A. D., & Kršák, M. (2023) · Substance Abuse · doi:10.1177/08897077231165619 · Cited by 3
Azar, P., Kim, J. J., Azarmju, F., Sirohi, K., Machado, J. M., Lau, A., Siu, J. T. P., Ignaszewski, M. J., Montaner, J. S. G., & Krausz, M. R. (2025) · Substance Use Research and Treatment · doi:10.1177/29768357251343612 · Cited by 2
Perioperative Considerations for Medications for Opioid Use Disorder
Harrison, T. K., Kornfeld, H., & Aggarwal, A. K. (2025) · Anesthesiology Clinics · doi:10.1016/j.anclin.2025.07.004 · Cited by 2
Costa, G. P. A., Sofuoglu, M., Compton, P. A., Ranganathan, M., Pittman, B. P., & Aquino, J. P. D. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02443-w · Cited by 2
Buprenorphine and acute pain in the fentanyl era: a graded competition model
Albert, O. M. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.06.040 · Cited by 2
Dana, S. R., Nichols, S. D., McCall, K. L., & Piper, B. J. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.22-00373 · Cited by 2
Armeni, K., Chambers, L. C., Peachey, A. M., Berk, J., Langdon, K. J., Peterson, L., Beaudoin, F. L., & Wightman, R. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-085888 · Cited by 2
Opioid Use Disorder in Pregnancy
Sanjanwala, A. R., & Harper, L. M. (2019) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000419 · Cited by 2
Principles of drug therapy: focus on opioids
Branford, R., Wighton, E., & Ross, J. R. (2015) · doi:10.1093/med/9780199656097.003.0091 · Cited by 2
Ghosh, A., Shaktan, A., Basu, D., Subodh, B. N., Naik, S. S., & Mattoo, S. K. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2225061 · Cited by 2
Buprenorphine: an old dog with new tricks
Ng, A. D., & Dickman, A. R. (2025) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000743 · Cited by 2
Buprenorphine in TheTreatment of Heroin Addiction /
Bell, J. R. (2012) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn20122502001 · Cited by 2
Houchard, G., Kullgren, J. G., Saphire, M. L., Porter, K. M., & Abel, S. (2019) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2019.1668903 · Cited by 2
Recent Advances in the Treatment of Opioid Use Disorders
Soyka, M. (2020) · Techniques in Neurosurgery & Neurology · doi:10.31031/tnn.2020.03.000572 · Cited by 2
Balasubramanian, S., Morley-Forster, P., & Yves Bureau, P. (2006) · Journal of Opioid Management · doi:10.5055/jom.2006.0024 · Cited by 3
Perioperative buprenorphine: are we asking the right questions?
Hurley, R. W. (2019) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2018-100205 · Cited by 2
Establishing Buprenorphine for Acute Postoperative Pain Management
Abelleira, A., & Hickey, T. R. (2025) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2025.2524688 · Cited by 2
Lower buprenorphine elimination rate constant is associated with lower opioid use
Elarabi, H. F., Lee, A. J., Adem, A., Elrasheed, A., Marsden, J., & Ghaferi, H. A. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06202-9 · Cited by 1
Rapid Initiation of Extended-Release Buprenorphine—Evidence and Barriers
Thakrar, A. P. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37331 · Cited by 1
Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases
Chow, K., Binkley, A., Meisner, J. A., Huo, S. C., & Hinton, M. S. (2026) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70178 · Cited by 1
Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address Them
Banks, M. L. (2026) · CNS Drugs · doi:10.1007/s40263-026-01300-0 · Cited by 1
Wang, T., Biswas, A. A., Zhang, F., Sun, R., & Hu, M. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115170 · Cited by 1
Managing patients with chronic pain and opioid addiction
Taylor, D. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-08111-3_4 · Cited by 1
Goulão, J. C.-B. (2013) · Acta Médica Portuguesa · doi:10.20344/amp.410 · Cited by 1
Buprenorphine and Opioid Rotation
Gourlay, D. L., & Heit, H. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6974-2_15 · Cited by 1
Pergolizzi, J. V. (2016) · Journal of Anesthesia and Surgery · doi:10.15436/2377-1364.16.022 · Cited by 1
Review article. Buprenorphine in the workers' compensation setting
Colameco, S., & Pohl, M. (2014) · Journal of Opioid Management · doi:10.5055/jom.2014.0215 · Cited by 1
Atkinson, T. J., Crumb, M., & Raouf, M. (2017) · Journal of Trauma & Treatment · doi:10.4172/2167-1222.1000359 · Cited by 1
Opioids and Related Medications
Atkinson, T. J., & Fudin, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-48464-8_12 · Cited by 1
Buprenorphine and Cardiac Surgery: Navigating the Challenges of Pain Management
Fernando, R. J., Graulein, D., Hamzi, R. I., Augoustides, J. G., Khalil, S., Sanders, J. A., Sibai, N., Hong, T. S., Kiwakyou, L. M., & Brodt, J. L. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.04.050 · Cited by 1
Positron Emission Tomography (PET) Imaging of Opioid Receptors
van Waarde, A., Absalom, A. R., Visser, A. K. D., & Dierckx, R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_21 · Cited by 1
Haines, A., Wood, K. C., Costello, J. L., & Tawil, T. (2023) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001205 · Cited by 1
Pritham, U. A. (2009) · DigitalCommons (California Polytechnic State University) · Cited by 1
Hadi, W. N. I. S. W. A., & Besar, J. A. (2022) · Jurnal Wacana Sarjana · doi:10.17576/jws.v6i1.482 · Cited by 1
Bart, G. B. (2013) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Abie Horowitz, M., Framer, A., Strang, J., & Taylor, D. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251371504
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
Buprenorphine as an Alternative for Treatment of Opioid Dependence
Sinchaisuk, S. (2005) · Journal of Basic and Applied Pharmacology
Buprenorphine Plasma Concentration in the Management of Opioid Dependence
Jutras‐Aswad, D., & Scimeca, M. M. (2011) · American Journal on Addictions · doi:10.1111/j.1521-0391.2011.00133.x
IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES
Lee, C., Varnäs, K., & Farde, L. (2013) · Wiley eBooks · doi:10.1002/9781118356845.ch20
Influencia genética en la respuesta analgésica a la buprenorfina transdérmica en cirugía torácica
Rincón, J. A. S. (2011) · Gredos (University of Salamanca) · doi:10.14201/gredos.110629
PET IMAGING OF THE PHARMACOKINETICS OF SMALL MOLECULAR‐WEIGHT DRUGS
Moerlein, S. M., & Tu, Z. (2013) · Wiley eBooks · doi:10.1002/9781118356845.ch7
Morlion, B. J., Pergolizzi, J. V., & Raffa, R. B. (2010) · Techniques in Regional Anesthesia and Pain Management · doi:10.1053/j.trap.2010.03.002
Neuroimaging of Nicotine Dependence: A Bioassay for Medications Development
Brody, A. L. (2006) · CRC Press eBooks · doi:10.1201/9781420005431.ch19
Molecular imaging of substance abuse
Schweinsburg, B. C., Schweinsburg, A. D., & Mason, G. F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.032
Pacini, M., Lubrano, S., & Maremmani, I. (2016) · Journal of Neuropsychopharmacology & Mental Health · doi:10.4172/2472-095x.1000111
مقایسة طول بیدردی و شدت آن با بوپرنورفین زیرزبانی و مورفین وریدی
علیجانپور, ا., ربیعی, س. م., نظیری, ف., بنیهاشم, ن., ربیعی, ا., & درودینیا, آ. (2016) · مجله آنستزیولوژی و مراقبتهای ویژه ایران
Searle, R. D., & Marshall, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-94482-1_15
Apelt, S. M. (2019) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.23930
Langwirksame Buprenorphinpräparate als neue pharmakologische Option bei Opiatabhängigkeit
Soyka, M. (2019) · Suchttherapie · doi:10.1055/a-1064-6188
Neue Therapieoptionen in der Substitutionsbehandlung
Soyka, M. (2020) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-020-2847-7
Neue Therapieoptionen in der Substitutionsbehandlung
Soyka, M. (2020) · CME · doi:10.1007/s11298-020-8112-8
Barnabé, K. (2020) · Mspace (University of Manitoba)
Gour, V., & sanwatshakar, S. (2021) · GLOBAL JOURNAL FOR RESEARCH ANALYSIS · doi:10.36106/gjra/2900310
Acute Pain Management in Patients with Opioid Dependence
Kitt, A., & Kim, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-77399-1_10
Optimization of patients with chronic pain and previous opioid use disorders
Chung, B. A., & Sweitzer, B. (2021) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000349
(2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-387-25733-0_14
(2012) · Wiley eBooks · doi:10.1002/9781118105955.ch28
(2008) · CRC Press eBooks · doi:10.1201/9780849378812.ch5
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23673-0.00006-9
(2015) · Elsevier eBooks · doi:10.1016/b978-3-437-23671-6.00006-7
Metadata
- Authors
- Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K.
- Affiliations
- Wayne State University (US)
- University of Utah (US)
- University of Michigan (US)
- Corresponding author
- Greenwald, Mark K
- Venue
- Neuropsychopharmacology
- Published
- 2003-05-30
- Volume
- 28
- Issue
- 11
- Pages
- 2000-2009
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2040327352
- Cited by
- 320
- References
- 44
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 23 · 2020: 20 · 2019: 20 · 2018: 11 · 2017: 14 · 2016: 3 · 2015: 12 · 2014: 11 · 2013: 22 · 2012: 14
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wayne State University
- U.S. Public Health Service (DA00254)
- National Institute on Drug Abuse (R01 DA 10100, P50DA000254, DA-00254, R01DA010100, P50 DA00254, P01DA000254)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- buprenorphine, heroin addiction, opioid maintenance treatment, dose-response relationship, opioid withdrawal symptoms
- MeSH terms
- Adult, Analysis of Variance, Buprenorphine, Dose-Response Relationship, Drug, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotic Antagonists, Tomography, Emission-Computed, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.